ABSTRACT Objective Due to their unique pathophysiological profile, patients with hypertrophic cardiomyopathy (HCM) undergoing non-cardiac surgery require additional attention to perioperative management. We sought to compare perioperative outcomes of patients with HCM undergoing non-cardiac surgery with a matched group patients without HCM. Methods This observational cohort study conducted at a tertiary care centre included patients with HCM (n=92, age 67 years, 54% men) undergoing intermediate-risk and high-risk non-cardiac surgeries between 1/2007 and 12/2013 (excluding <18 years, prior septal myectomy/ alcohol ablation, low-risk surgery) who were 1:2 matched (based on age, gender, type and time of noncardiac surgery) with patients without HCM (n=184, median age 65 years, 53% men). A composite endpoint (30-day postoperative death, myocardial infarction, stroke, in-hospital decompensated congestive heart failure (CHF) and rehospitalisation within 30 days) and postoperative atrial fibrillation (AF) were recorded.
INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a commonly inherited cardiomyopathy with a varied phenotypic expression ranging from asymptomatic status to progressive congestive heart failure (CHF) to sudden death which occurs in <1%/year. [1] [2] [3] [4] A unique feature of HCM is the presence of dynamic left ventricular outflow tract (LVOT) obstruction, observed in ∼70% patients, 5 and is independently associated with adverse HCM-related outcomes. [6] [7] [8] The degree of LVOT obstruction can fluctuate tremendously depending upon various factors, including alterations in LV preload and afterload, LV cavity size and heart rate. In addition, patients with HCM have a higher incidence of diastolic dysfunction, subendocardial ischaemia and frequent non-sustained ventricular tachycardia and sustained ventricular tachycardia/fibrillation. 3 4 These characteristics warrant additional attention when patients with HCM undergo non-cardiac surgery, with regard to risk stratification and perioperative management. Data regarding perioperative management and outcomes in patients with HCM undergoing non-cardiac surgery are limited, and often conflicting. [9] [10] [11] [12] [13] [14] One study, based on a 20% sample of patients operated in US community hospitals, found that patients with HCM undergoing non-cardiac surgery were at high risk for perioperative death, CHF and acute myocardial infarction (MI). 10 Other studies did not report perioperative deaths, but did notice slightly increased risk of CHF. 11 12 For patients with HCM, current practice at our institution is to get a cardiovascular consultation prior to proceeding with intermediate-risk or high-risk non-cardiac surgery. At our experienced HCM centre, we sought to assess (a) intraoperative characteristics and perioperative outcomes in patients with HCM undergoing intermediate-risk or high-risk non-cardiac surgery and (b) compare them with matched patients without HCM undergoing similar type of non-cardiac surgery.
METHODS

Study sample
This was an observational cohort study of 276 patients undergoing intermediate-risk and high-risk non-cardiac surgeries 15 at our tertiary care between 1/2007 and 12/2013 (out of a total of >5000 patients). High-risk surgeries included aortic and major vascular surgery, while intermediate-risk surgeries included carotid endarterectomy, head and neck surgery, intraperitoneal surgery, intrathoracic surgery and orthopaedic surgery. Baseline clinical data were prospectively entered into the electronic medical records and extracted by manual review of these records. The study was approved by the institutional review board with waiver of individual informed consent, due to its observational nature. The study sample was divided into two matched groups, as follows: HCM group: This group consisted of 92 adult (≥18 years) patients with documented HCM. The diagnosis of HCM was made by cardiologists experienced in this disease, based on typical clinical, electrocardiographic and echocardiographic features, with LV wall thickness ≥15 mm occurring in the absence of any other cardiac or systemic disease that could have been responsible for the hypertrophy. 3 4 The following patients were excluded: (a) surgical myectomy or alcohol septal ablation prior to the contemplated non-cardiac surgery (n=15), (b) LV ejection fraction <50% or concomitant moderate or higher degree of aortic or mitral stenosis on initial echocardiogram (n=3) and (c) hypertensive heart disease of elderly (n=10). Hypertensive heart disease of elderly was defined as a long-standing history of hypertension, characteristic sigmoid-shaped septal hypertrophy and concomitant dynamic LVOT obstruction. [16] [17] [18] These patients were excluded, as they have a different pathophysiological and genetic profile. By study design, we also excluded 95 patients with HCM who underwent low-risk non-cardiac surgery. Additionally, no patient had advanced symptoms related to HCM-related LVOT obstruction prior to the contemplated non-cardiac surgery, to warrant invasive therapies such as septal myectomy or alcohol ablation. Matched control group: This group consisted on 184 patients without HCM who were rigorously matched in a 2:1 fashion, based on age, gender, type and time of non-cardiac surgery. The matching was performed after initial stratification of patients into four strata based on gender and age (female, age ≤median; female, age >median; male, age ≤median and male, age >median). Within each strata, patients were matched two controls to one patient with HCM and without overlap within ±2 years of age using a random number generator to prevent any group bias. The matched groups were created in a blinded fashion without knowledge of any additional data.
All patients with HCM underwent comprehensive echocardiograms using commercially available instruments at individual sites. Maximal end-diastolic LV wall thickness, LV dimensions and left atrial diameter were measured according to guidelines. 19 Resting LVOT peak velocity was measured by continuous-wave Doppler echocardiography, and resting LVOT pressure gradient was estimated by using the simplified Bernoulli equation. Care was taken to avoid contamination of the LVOT waveform by mitral regurgitation. In patients with resting LVOT gradients <30 mm Hg, provocative manoeuvres, including Valsalva, amyl nitrite and/or exercise echocardiography, were used to provoke LVOT gradient. In patients with resting peak LVOT gradient >100 mm Hg, provocative manoeuvres were not used. Maximal LVOT gradient was recorded and defined as the highest recorded gradient (either resting or provoked, including exercise) in a given patient. 8 20 Operative data Standard preoperative data, including revised cardiac risk index, 15 American Society of Anaesthesiologists (ASA) risk score 21 and Mallampati score for intubation, 22 were prospectively entered into the patients' electronic and perioperative anaesthesia records, and retrieved manually in each patient. In addition, intraoperative pharmacological (type of anaesthesia, fluids and use of vasopressors) and physiological (vital signs, estimated blood loss, fluid balance) data were obtained by manual review of anaesthesia records. We also recorded the intraoperative time duration for which the patient remained hypotensive (systolic blood pressure <90 mm Hg) or tachycardiac (heart rate >100 bpm). Data were reviewed in detail to exclude artefactual intraoperative readings.
Outcomes
Primary outcome was a composite of death, stroke, MI, newonset symptomatic in-hospital CHF or rehospitalisation for CHF exacerbation (requiring intravenous diuresis with haemodynamic monitoring), all within 30 days postoperatively. Time to first event was used as a censoring cut-off. Postoperative atrial fibrillation (AF) and venous thromboembolism within 30 days were also recorded. Decompensated CHF (as an inpatient or resulting in rehospitalisation) due to rapid postoperative AF was not included as a primary outcome.
Statistical analysis
Patient and procedural characteristics were stratified according to the presence or absence of HCM. Because significant proportions of continuous variables were non-parametric, all are expressed as median with IQR, with differences compared using Student's paired t test (for normal variables) and the Wilcoxon signed-rank test (for non-normal variables). Categorical data are expressed as percentages, and differences in their distribution were compared using McNemar's test. To determine the association between relevant predictors and 30-day composite events, univariable and multivariable logistic regression analyses were performed. To account for matched pair design, conditional logistic regression analysis was performed. Statistical analysis was performed using SPSS V.11.5 (SPSS, Chicago, Illinois, USA). A p value of <0.05 was considered significant.
RESULTS
The baseline clinical characteristics are shown in table 1. The three groups were well matched for relevant non-HCM related baseline characteristics, as well as for anaesthesia-specific factors; however, a higher proportion of patients with HCM was on β-blockers (58% vs 39%, p=0.003). The breakdown of various surgeries was as follows (and similar for the two groups): high-risk vascular (22%) and intermediate-risk surgeries (carotid endarterectomy (3%), head and neck surgery (11%), intraperitoneal surgery (26%), intrathoracic surgery (9%) and orthopaedic (29%)) surgery. All patients were thoroughly evaluated by experienced clinicians and cleared for non-cardiac surgery, according to guidelines. 15 Specific echocardiographic characteristics of the HCM group were analysed in all 92 patients. Median left ventricular ejection fraction (LVEF), maximal LV wall thickness and provokable LVOT gradient were 60% (59, 65), 1.7 cm (1.5, 2.0) and 64 mm Hg (25, 100), respectively. High provokable LVOT gradient (>30 mm Hg), systolic anterior motion of mitral valve and ≥II+ mitral regurgitation were seen in 53 (58%), 57 (62%) and 22 (24%) patients with HCM, respectively. In addition, 86 (93%) patients had stage I and 6 (7%) had stage II diastolic dysfunction.
Intraoperative data in the two groups are shown in table 2. Patients with HCM had significantly less intraoperative haemodynamic shifts, suggested by a lower duration of hypotensive (systolic blood pressure <90 mm Hg) and tachycardiac (heart rate >100 bpm) episodes. A significantly higher percentage of patients with HCM received etomidate for induction of anaesthesia (32% vs 14%, p=0.002). However, the groups were well matched for total duration of surgery, estimated blood loss and urine output.
Outcomes
At 30 days postoperatively, 42 (15%) patients had composite primary events. The data on composite and individual primary events at 30 days, in the two subgroups, are shown in table 3. Presence of HCM, high-risk versus intermediate-risk noncardiac surgery, high ASA risk score and intraoperative duration of hypotension (systolic blood pressure <90 mm Hg) were independently associated with a significantly higher proportion of primary composite events (all p<0.05). Of note, a higher proportion of patients undergoing high-risk surgery had a composite event versus intermediate risk (53% vs 16%, p<0.01), with no differences between patients with and without HCM. Additionally, occurrence of postoperative AF was significantly higher in patients with HCM versus without HCM (4 (4%) vs 0, p=0.01), while the incidence of postoperative venous thromboembolism was slightly higher but not statistically significant in patients with HCM versus without HCM (5 (5%) vs 4 (2%), p=0.1).
We further analysed the association between composite primary events (n=20) and potential predictors in patients with HCM (n=92 
DISCUSSION
In the current study, we report the baseline and intraoperative characteristics, along with 30-day postoperative outcomes in patients with HCM undergoing intermediate-risk and high-risk non-cardiac surgeries at an experienced HCM centre, matched in a 1:2 fashion with a control sample undergoing similar surgeries. We demonstrate that the non-HCM related baseline characteristics were very similar in each group, except for the higher proportion of β-blockers in HCM group. Similarly, the intraoperative characteristics were well matched in patients with HCM versus those without HCM, except for a lower use of ephedrine and lower haemodynamic shifts (hypotensive and/or tachycardiac episodes) in patients with HCM, as would be hoped for during non-cardiac surgery. In addition, etomidate was administered in a higher proportion of patients with HCM versus patients without HCM, as it is known to cause less haemodynamic perturbances during induction of anaesthesia. Despite that, there was a higher proportion of 30-day primary events in patients with HCM versus matched patients without HCM, along with a higher proportion of AF within 30 days postoperatively. However, the incidence of individual hard endpoints such as death, stroke and MI was very low in both groups and not significantly different. The significant differences in primary composite events were predominantly driven by CHF during the hospital stay and rehospitalisation. We also demonstrate that presence of HCM, along with higher ASA risk score, higher risk of non-cardiac surgery and greater duration of intraoperative hypotension were independently associated with higher composite primary events. Within the subgroup of patients with HCM, we also demonstrate that higher provokable LVOT gradient and greater duration of intraoperative hypotension were associated with higher incidence of composite primary events. The median age of the current HCM sample was significantly higher than previous reports coming from our institution. 8 23 24 However, that would be expected, considering the fact that the primary hypothesis involved identifying patients with HCM that needed non-cardiac surgery. Similarly, the number of patients with HCM and hypertension was also significantly higher, again reflecting the primary hypothesis of these patients needing non-cardiac surgery. On the other hand, care was taken to ensure that these patients did not indeed reflect hypertensive heart disease of elderly, as these have a different pathophysiological profile than true patients with HCM. [16] [17] [18] However, one can argue, based on the findings of the current study, that a major driver of outcomes in patients with HCM is intraoperative haemodynamic shift, aggravating dynamic LVOT obstruction; and that is common between true HCM and hypertensive heart disease of elderly. Hence, patients with hypertensive heart disease of elderly, with concomitant LVOT obstruction, would also be likely managed in a similar fashion.
Patients with HCM present unique challenges during intraoperative management when undergoing non-cardiac surgery, mostly due to the associated dynamic LVOT obstruction and issues with LV compliance and diastolic dysfunction. LVOT gradient can fluctuate tremendously and may further be exacerbated by hypovolaemia. As such, maintaining euvolaemia during surgery becomes of primary importance in patients with HCM, because a decrease in preload or afterload can unmask a provokable LVOT gradient, as can sympathetic stimulation, which is seen frequently, as during surgery. Also, intravenous phenylephrine (or another pure vasoconstricting agent) is recommended for the treatment of acute hypotension in patients with obstructive HCM who do not respond to fluid administration. 3 4 Indeed, careful selection of anaesthesia induction agents, such as etomidate, which cause less haemodynamic perturbances would also be potentially very helpful. Due to these concerns, and the fact that HCM is associated with diastolic dysfunction, increased incidence of coronary ischaemia, ventricular arrhythmias and sudden death, most patients with HCM scheduled for noncardiac surgery require detailed preoperative evaluation and close intraoperative monitoring. Despite the aforementioned concerns, very limited data exist regarding perioperative management and outcomes of patients with HCM undergoing non-cardiac surgery. A prior study of 30 patients with HCM did not find any in-hospital death or MI after non-cardiac surgery. 11 Haering et al 12 studied 77 patients with HCM who underwent non-cardiac surgery and found no perioperative deaths, although they did note an increased incidence of postoperative CHF. However, these were much smaller sized studies, where the outcomes were not compared with similarly matched patients without HCM. Hreybe et al 10 compared 227 patients with HCM with 554 non-HCM controls, and found that having HCM increased the risk of in-hospital death or MI after non-cardiac surgery. However, the study sample was derived from the National Inpatient Sample, which represents the largest publicly available all-payer US inpatient database, representing ∼20% sample from US community hospitals, where there is potential lack of expertise in managing the nuances associated with HCM-related non-cardiac surgery. Given the paucity of data at experienced centres, we decided to investigate outcomes after non-cardiac surgery in patients with HCM at our institute, which is well experienced in managing the full spectrum of patients with HCM, especially taking into account the higher incidence of hard events from a previous sample. 10 The results of the current study underscore the importance of experience in managing patients with HCM, 23 25 26 not just HCM-based symptoms, but even when they need non-cardiac surgery. While the current results demonstrate a higher rate of composite primary events in patients with HCM, even at our tertiary care centre, it is important to note that the hard events such as death, MI and stroke were very low and not significantly different from patients without HCM. There was a higher rate of CHF and readmissions (related to CHF) likely due to variability in dietary/fluid intake in the perioperative period, to which patients with HCM were likely less able to adapt due to their unique pathophysiology. Further, unlike previous reports, the current study has the added advantage that all included patients with HCM had preoperative echocardiograms, thereby allowing us to assess the severity of HCM. This has helped us to better stratify the risk in these patients. Also, previous studies have not specified whether the patients with HCM they included had undergone septal reductive therapy prior to non-cardiac surgery. In the current study, no patient with HCM undergoing non-cardiac surgery had a clinical indication to invasively alleviate LVOT obstruction either by myectomy or alcohol ablation. In addition, we also present detailed intraoperative management of HCM cases and the matched cohorts, with haemodynamic variables, fluid management and type of anaesthesia. For assessing outcomes, we extended the timeline to the standard 30 days postoperatively as opposed to assessing only perioperative in-hospital events. 10 
Clinical implications
Distinct from the previous data reported out of community hospitals, patients with HCM undergoing non-cardiac surgery at an experienced HCM centre have a very low rate of hard perioperative events such as death, MI or stroke. However, they have a significantly higher rate of 30-day composite events (driven mostly by CHF) and AF. In addition to the standard perioperative risk, it appears that intraoperative haemodynamic shifts appear to play a significant role in the occurrence of these events. During intraoperative management of HCM cases, particular attention must be paid to minimising haemodynamic shifts, including at the time of anaesthesia induction.
Limitations
This was an observational study with its inherent selection biases. However, we performed a rigorous and blinded process of matching to have a fair comparison. Despite a rigorous matching process, it is possible that there were additional comorbidities, potentially impacting outcomes that were different between the two groups and unaccounted for. The individual event rate was very low, as would be expected. This could potentially result in a type II error due to a small sample size. In our study, we excluded patients with HCM who had undergone septal reduction therapy prior to non-cardiac surgery. Therefore, our results do not apply to this particular subgroup of patients with HCM. The current study cohort was significantly older and had a higher proportion of hypertensives compared with the previously described HCM studies. 8 23 24 However, that would be expected, considering the fact that the primary hypothesis involved identifying those patients with HCM that needed non-cardiac surgeries like vascular, abdominal and orthopaedic procedures. Additionally, at the time of patient selection, care was taken to ensure that these patients did not indeed reflect hypertensive heart disease of elderly. Our tertiary care centre is well experienced in managing patients with HCM, non-cardiac surgery and postoperative care, and hence, the results might not be reproducible in smaller lesser experienced centres. However, that itself underscores the need for such patients being managed at a centre with an experienced multidisciplinary team. Based on the findings of the current study, avoiding intraoperative haemodynamic shifts could also benefit such hypertensive patients who also have dynamic LVOT obstruction.
CONCLUSION
In a study of patients with HCM undergoing high-risk and intermediate-risk non-cardiac surgeries at an experienced HCM centre, there is a very low rate of hard perioperative events like death, MI and stroke. When compared with a matched cohort of patients without HCM, patients with HCM have a higher risk of composite events, including rehospitalisation. During intraoperative management of HCM cases, particular attention must be paid to minimising haemodynamic shifts to ensure good perioperative outcomes. Further studies are warranted to confirm the findings of the current study.
